Skip to Main content Skip to Navigation
Journal articles

Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.

Abstract : Angiogenesis targeting is an attractive approach for cancer treatment. Vascular endothelial growth factor receptor 2 (VEGFR2) is such an important target that is overexpressed in tumor vasculature compared to the endothelium cells of resting blood vessels and blocking of its signaling inhibits neovascularization and tumor metastasis. Immunotoxins represent a promising group of targeted therapeutics to combat tumors. They consist of an antibody linked to a toxin and are designed to kill specifically the tumor cells. In this study, we fused a VEGFR2-specific Nanobody, the antigen-binding single-domain fragment derived from functional Heavy-chain antibody of Camelidae, to the truncated form of Pseudomonas exotoxin A and evaluated its ability to bind the VEGFR2 molecule on the cell surface. We demonstrate that this immunotoxin inhibits the proliferation of VEGFR2-expressing cells in vitro. This finding is considered to be a significant achievement in tumor therapy and it forms a basis for further studies in animal models.
Document type :
Journal articles
Complete list of metadatas

Cited literature [26 references]  Display  Hide  Download

https://hal-riip.archives-ouvertes.fr/pasteur-00821222
Contributor : Morteza Karimipour <>
Submitted on : Wednesday, May 8, 2013 - 6:42:20 AM
Last modification on : Wednesday, September 23, 2020 - 10:48:02 AM
Long-term archiving on: : Tuesday, April 4, 2017 - 6:02:14 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Mahdi Behdani, Sirous Zeinali, Morteza Karimipour, Hossein Khanahmad, Steve Schoonooghe, et al.. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.. New Biotechnology, Elsevier, 2013, 30 (2), pp.205-9. ⟨10.1016/j.nbt.2012.09.002⟩. ⟨pasteur-00821222⟩

Share

Metrics

Record views

193